Literature DB >> 27022022

A Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface Targets.

John J Rhoden1, Gregory L Dyas2, Victor J Wroblewski2.   

Abstract

Despite the increasing number of multivalent antibodies, bispecific antibodies, fusion proteins, and targeted nanoparticles that have been generated and studied, the mechanism of multivalent binding to cell surface targets is not well understood. Here, we describe a conceptual and mathematical model of multivalent antibody binding to cell surface antigens. Our model predicts that properties beyond 1:1 antibody:antigen affinity to target antigens have a strong influence on multivalent binding. Predicted crucial properties include the structure and flexibility of the antibody construct, the target antigen(s) and binding epitope(s), and the density of antigens on the cell surface. For bispecific antibodies, the ratio of the expression levels of the two target antigens is predicted to be critical to target binding, particularly for the lower expressed of the antigens. Using bispecific antibodies of different valencies to cell surface antigens including MET and EGF receptor, we have experimentally validated our modeling approach and its predictions and observed several nonintuitive effects of avidity related to antigen density, target ratio, and antibody affinity. In some biological circumstances, the effect we have predicted and measured varied from the monovalent binding interaction by several orders of magnitude. Moreover, our mathematical framework affords us a mechanistic interpretation of our observations and suggests strategies to achieve the desired antibody-antigen binding goals. These mechanistic insights have implications in antibody engineering and structure/activity relationship determination in a variety of biological contexts.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Keywords:  antibody; antibody engineering; avidity; bispecific antibody; cooperativity; kinetics; mathematical modeling; multifunctional protein

Mesh:

Substances:

Year:  2016        PMID: 27022022      PMCID: PMC4900278          DOI: 10.1074/jbc.M116.714287

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

Review 1.  Antibody vectors for imaging.

Authors:  Tove Olafsen; Anna M Wu
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

2.  Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays.

Authors:  E N Kaufman; R K Jain
Journal:  Cancer Res       Date:  1992-08-01       Impact factor: 12.701

3.  Distances between the antigen-binding sites of three murine antibody subclasses measured using neutron and X-ray scattering.

Authors:  T R Sosnick; D C Benjamin; J Novotny; P A Seeger; J Trewhella
Journal:  Biochemistry       Date:  1992-02-18       Impact factor: 3.162

Review 4.  Scavenger receptors in homeostasis and immunity.

Authors:  Johnathan Canton; Dante Neculai; Sergio Grinstein
Journal:  Nat Rev Immunol       Date:  2013-08-09       Impact factor: 53.106

Review 5.  Functions of lipid rafts in biological membranes.

Authors:  D A Brown; E London
Journal:  Annu Rev Cell Dev Biol       Date:  1998       Impact factor: 13.827

6.  Immunoglobulin isotype influences affinity and specificity.

Authors:  Arturo Casadevall; Alena Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-23       Impact factor: 11.205

7.  Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.

Authors:  Jamie B Spangler; Mandana T Manzari; Elizabeth K Rosalia; Tiffany F Chen; K Dane Wittrup
Journal:  J Mol Biol       Date:  2012-06-15       Impact factor: 5.469

8.  Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.

Authors:  Yu Zhou; Anne-Laure Goenaga; Brian D Harms; Hao Zou; Jianlong Lou; Fraser Conrad; Gregory P Adams; Birgit Schoeberl; Ulrik B Nielsen; James D Marks
Journal:  Mol Cancer Ther       Date:  2012-05-07       Impact factor: 6.261

9.  Improving target cell specificity using a novel monovalent bispecific IgG design.

Authors:  Yariv Mazor; Vaheh Oganesyan; Chunning Yang; Anna Hansen; Jihong Wang; Hongji Liu; Kris Sachsenmeier; Marcia Carlson; Dhanesh V Gadre; Martin Jack Borrok; Xiang-Qing Yu; William Dall'Acqua; Herren Wu; Partha Sarathi Chowdhury
Journal:  MAbs       Date:  2015       Impact factor: 5.857

10.  Dynamic redistribution of raft domains as an organizing platform for signaling during cell chemotaxis.

Authors:  Concepción Gómez-Moutón; Rosa Ana Lacalle; Emilia Mira; Sonia Jiménez-Baranda; Domingo F Barber; Ana C Carrera; Carlos Martínez-A; Santos Mañes
Journal:  J Cell Biol       Date:  2004-02-23       Impact factor: 10.539

View more
  13 in total

Review 1.  Tumor-derived extracellular vesicles: molecular parcels that enable regulation of the immune response in cancer.

Authors:  Colin Sheehan; Crislyn D'Souza-Schorey
Journal:  J Cell Sci       Date:  2019-10-15       Impact factor: 5.285

2.  Multivalent Ligand Binding to Cell Membrane Antigens: Defining the Interplay of Affinity, Valency, and Expression Density.

Authors:  Clifford M Csizmar; Jacob R Petersburg; Thomas J Perry; Lakmal Rozumalski; Benjamin J Hackel; Carston R Wagner
Journal:  J Am Chem Soc       Date:  2018-12-17       Impact factor: 15.419

3.  Synergistic Neutralization of Pertussis Toxin by a Bispecific Antibody In Vitro and In Vivo.

Authors:  Ellen K Wagner; Xianzhe Wang; Andre Bui; Jennifer A Maynard
Journal:  Clin Vaccine Immunol       Date:  2016-11-04

4.  A kinetic proofreading model for bispecific protein degraders.

Authors:  Derek W Bartlett; Adam M Gilbert
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-10-22       Impact factor: 2.745

5.  A general model of multivalent binding with ligands of heterotypic subunits and multiple surface receptors.

Authors:  Zhixin Cyrillus Tan; Aaron S Meyer
Journal:  Math Biosci       Date:  2021-10-09       Impact factor: 2.144

Review 6.  Key metrics to expanding the pipeline of successful antibody-drug conjugates.

Authors:  Ian Nessler; Bruna Menezes; Greg M Thurber
Journal:  Trends Pharmacol Sci       Date:  2021-08-26       Impact factor: 17.638

7.  Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.

Authors:  Carolin Sellmann; Achim Doerner; Christine Knuehl; Nicolas Rasche; Vanita Sood; Simon Krah; Laura Rhiel; Annika Messemer; John Wesolowski; Mark Schuette; Stefan Becker; Lars Toleikis; Harald Kolmar; Bjoern Hock
Journal:  J Biol Chem       Date:  2016-09-30       Impact factor: 5.157

8.  A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.

Authors:  Amita Patnaik; Michael Gordon; Frank Tsai; Kyriakos P Papadopoulos; Drew Rasco; Muralidhar Beeram; Siqing Fu; Filip Janku; Scott M Hynes; Sushma R Gundala; Melinda D Willard; Wei Zhang; Aimee Bence Lin; David Hong
Journal:  Cancer Chemother Pharmacol       Date:  2018-06-20       Impact factor: 3.333

9.  Target-Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy.

Authors:  Johannes Schropp; Antari Khot; Dhaval K Shah; Gilbert Koch
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-01-08

10.  A computational diffusion model to study antibody transport within reconstructed tumor microenvironments.

Authors:  Ana Luísa Cartaxo; Jaime Almeida; Emilio J Gualda; Maria Marsal; Pablo Loza-Alvarez; Catarina Brito; Inês A Isidro
Journal:  BMC Bioinformatics       Date:  2020-11-17       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.